Immunogenicity and Safety of a Booster Vaccination With a Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Healthy Adults Volunteers Fully Vaccinated Followed by an Extension Period to Study a Fourth Dose Administration.

NCT05142553 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

887

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19
SARS-CoV-2 Acute Respiratory Disease

Interventions

BIOLOGICAL: COVID-19 Vaccine HIPRA
BIOLOGICAL: Cominarty (Pfizer-BioNtech)

Sponsor

Hipra Scientific, S.L.U

Collaborators

[object Object]